Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gadoquatrane→

Gadoquatrane Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Gadolinium-based MRI contrast agenttetrameric macrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact tetrameric macrocyclic gadolinium complex is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast chelate, not a therapeutic agent.
Indications / reported uses
  • MRI contrast enhancement for adults and paediatric patients with known or suspected abnormalities of the central nervous system and other body regions under the applicable product authorisation; confirm current country-specific label and approval status before assigning precise indications

Sources: US DailyMed — Gadoquatrane product information · NLM MeSH — Gadoquatrane · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gadolinium-based MRI contrast agent; tetrameric macrocyclic non-ionic gadolinium chelate

Mechanism of action

The intact tetrameric macrocyclic gadolinium complex is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast chelate, not a therapeutic agent.

General use cases

  • MRI contrast enhancement for adults and paediatric patients with known or suspected abnormalities of the central nervous system and other body regions under the applicable product authorisation; confirm current country-specific label and approval status before assigning precise indications

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Gadoquatrane Environmental Risk Assessment (ERA) (the Gadoquatrane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.